Drug intelligence / Profile preview

Interleukin-31 monoclonal antibody

Development stage: Preclinical
Lead developer: Chugai Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

This drug would be a monoclonal antibody targeting interleukin-31 (IL-31), a cytokine involved in inflammation, pruritus, and skin diseases. IL-31 acts on both immune and non-immune cells and is implicated in signaling pro-inflammatory cytokines, cell proliferation, and tissue remodeling[1]. Monoclonal antibodies targeting IL-31 or its receptor may be used to treat conditions like atopic dermatitis and other pruritic diseases[3][4].

Other names: Anti-human IL-31 monoclonal antibodies

Targets

IL31 (IL-31)IL31RA (IL-31 receptor alpha)

Beyond the preview

Go deeper on Interleukin-31 monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-31 monoclonal antibody.

Explore the full profile